Dr. Benjamin (Ben) Laser is an extensively trained and knowledgeable radiation oncologist in The Institute for Cancer Care at Mercy.
The Endometriosis Center at Mercy Medical Center offers patients a highly skilled team of surgeons and specialists experienced in the diagnosis and treatment of endometriosis.
Named a Best Regional Hospital in Gastroenterology, Mercy Medical Center is home to The Institute for Digestive Health and Liver Disease, offering dedicated specialists and advanced treatment options.
Dr. Armando Sardi is widely regarded for his training and skills in utilizing Hyperthermic intraperitoneal chemotherapy (HIPEC) to treat advanced stages of abdominal cancer (peritoneal surface malignancies).
Mercy offers emergency care on the Downtown Baltimore campus 24 hours a day, 7 days a week (410-332-9477) with access to a trained emergency medicine team, diagnostic services and consultations with specialists.
In case of an Emergency, Dial 911 and follow the instructions of the EMS (Emergency Medical Services) team.
Mercy Medical Center's downtown campus includes our Main Hospital - The Mary Catherine Bunting Center, McAuley Plaza and The Weinberg Center.
General visiting hours at Mercy are 11:00 am to 8:30 pm. Hours vary by floor, please check with the nursing staff or call 410-332-9555.
Currently Displaying: Active Clinical Trials
The Aromatase Inhibitor Cardiovascular Health Evaluation (ACE) Study will examine the cardiovascular (heart) health of breast cancer patients during their first year of aromatase inhibitor (AI) treatment and determine whether AIs affect the cardiovascular health of African-American breast cancer patients differently than Caucasian breast cancer patients. This study is for women diagnosed with postmenopausal, early-stage (stages I and II) breast cancer who are initiating AI (Femara, Arimidex or Aromasin) treatment. Funded by Susan G. Komen for the Cure®.
The purpose of this phase III trial to determine whether the addition of daily BKM120 to fulvestrant (also known as Faslodex®) is effective and safe in treating patients with hormone receptor-positive HER2-negative locally advanced or metastatic breast cancer whose disease has progressed on or after aromatase inhibitor treatment. (Novartis CBKM120F2302, ClinicalTrials.gov ID#: NCT01610284)
The purpose of this phase II trial is to evaluate the efficacy and tolerability of oral veliparib, a PARP inhibitor, in subjects with BRCA1 or BRCA2 mutation and metastatic breast cancer. Subjects will be randomized to one of three treatment regimens: Veliparib in combination with Temozolomide (TMZ), Veliparib in combination with carboplatin and paclitaxel, or placebo in combination with carboplatin and paclitaxel. (AbbVie M12-895, ClinicalTrials.gov ID#: NCT01506609)
This randomized phase III trial is studying carboplatin, paclitaxel, bevacizumab (if appropriate) in order to compare how well they work with or without cetuximab in treating patients with stage IV or recurrent non-small cell lung cancer. This study is for newly diagnosed stage IV disease OR recurrent disease after prior surgery and/or irradiation. (SWOG S0819; ClinicalTrials.gov ID#: NCT00946712)
This study is designed for patients desiring nipple reconstruction following surgery for breast cancer and breast reconstruction. Eligible patients will receive a surgical procedure to reconstruct one or both nipples utilizing the COOK® Biodesign® Plastic Surgery Matrix. The study is designed to evaluate the benefit of this device in achieving effective and aesthetic nipple reconstruction. Patients will be evaluated at the time of the procedure and at 1 week, 4 weeks, 3 months, 6 months, and 12 months after surgery to examine the projection of their reconstructed nipple(s) and patient satisfaction (Cook Medical Study 09-009; Clinicaltrials.gov ID#: NCT01216319).
This randomized phase III trial is studying how well giving hormone therapy together with or without everolimus works in treating patients with high-risk, hormone receptor-positive, HER2-negative breast cancer. (SWOG S1207, ClinicalTrials.gov ID#: NCT01674140)
This is a phase III trial comparing trastuzumab + pertuzumab + taxane following versus trastuzumab emtansine + pertuzumab, following anthracyclines as adjuvant therapy in patients with operable HER2-positive primary breast cancer. (Roche BO28407, ClinicalTrials.gov ID#: NCT01966471
This phase III study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab (also known as Herceptin®) as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in the breast or axillary lymph nodes following preoperative therapy. (Roche BO27938 / NSABP B-50-I / GBG 77, ClinicalTrials.gov ID#: NCT01772472)
The primary object of this phase II trial is to determine if administration of lisinopril (an ACE Inhibitor) or Coreg CR® (β-blocker), compared to placebo, will reduce the incidence of trastuzumab-induced cardiotoxicity, as measured by LVEF, in patients receiving adjuvant, or neoadjuvant, therapy for HER2-positive breast cancer (SCUSF 0806, ClinicalTrials.gov ID#: NCT01009918)
The primary aim of the study is to determine the microbiological environment of the peritoneal tissues of patients undergoing cytoreductive surgery with intraoperative hyperthermic chemotherapy for appendix cancer with peritoneal spread.
This is a prospective, observational study that will assess the impact of MammaPrint on treatment decisions (chemotherapy plus endocrine versus endocrine alone) in patients with an intermediate score by Oncotype DX®. MammaPrint is an FDA-cleared test that may be used to identify which early-stage breast cancer patients are at risk of distant recurrence following surgery. (Clinicaltrials.gov ID#: NCT01617954)
The purpose of this study is to compare the effect of adding the drug trastuzumab (also called Herceptin®) to breast radiation therapy versus radiation alone. Trastuzumab has been shown to block the HER2 protein and to slow down or stop the growth of HER2-postive “invasive” breast cancers. Radiation therapy is the standard treatment for patients with DCIS. (NSABP B-43, Clinicaltrials.gov ID#: NCT00769379)
The objective of this phase III clinical trial is to determine the effect of endocrine therapy with or without chemotherapy in patients with node-positive breast cancer who do not have high Recurrence Scores (RS) by Oncotype DX®. (SWOG S1007, Clinicaltrials.gov ID#: NCT01272037)
The doctors of The Prevention & Research Center at Mercy Medical Center in Baltimore, Maryland, offers patients and their families a number of distinctive cancer wellness services and programs to support their recovery and to help their families manage life after cancer treatment, including Be Well, Stay Healthy™, Be Well, Stay Healthy KIDS!™, Cancer Genetic Counseling, Cancer Recovery Program and Cancer Survivor Consultation Service.
Dr. Kathy Helzlsouer is a nationally recognized expert in cancer epidemiology, cancer genetic counseling and clinical research.